KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Enterprise Value (2016 - 2025)

AbbVie (ABBV) has disclosed Enterprise Value for 14 consecutive years, with -$5.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 5.46% to -$5.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.2 billion, a 5.46% increase, with the full-year FY2025 number at -$5.2 billion, up 5.46% from a year prior.
  • Enterprise Value was -$5.2 billion for Q4 2025 at AbbVie, up from -$5.7 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$5.1 billion in Q1 2025 to a low of -$18.1 billion in Q1 2024.
  • A 5-year average of -$9.3 billion and a median of -$9.0 billion in 2022 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 76.29% in 2021, then crashed 169.97% in 2024.
  • AbbVie's Enterprise Value stood at -$9.8 billion in 2021, then grew by 6.18% to -$9.2 billion in 2022, then crashed by 38.96% to -$12.8 billion in 2023, then surged by 56.84% to -$5.5 billion in 2024, then rose by 5.46% to -$5.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Enterprise Value are -$5.2 billion (Q4 2025), -$5.7 billion (Q3 2025), and -$6.5 billion (Q2 2025).